The prognosis for T-ALL patients varies based on several factors, including age, overall health, and response to treatment. Children and young adults generally have a better prognosis compared to older adults. Advances in treatment have significantly improved survival rates, but long-term monitoring is essential for managing potential relapses and side effects of treatment.
